Harvard Bioscience (HBIO) Capital Expenditures Growth (3y) (2013 - 2026)
Harvard Bioscience (HBIO) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -18.96% |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -11.61% |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | - |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 5.31% |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -31.75% |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | - |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 5.49% |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -21.70% |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -6.01% |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | 23.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.90% |
| Dec 31, 2025 | 24.09% |
| Sep 30, 2025 | -22.34% |
| Jun 30, 2025 | -41.39% |
| Mar 31, 2025 | 2.89% |
| Dec 31, 2024 | -5.62% |
| Sep 30, 2024 | 22.39% |
| Jun 30, 2024 | 58.35% |
| Mar 31, 2024 | 62.25% |
| Dec 31, 2023 | 134.94% |
| Sep 30, 2023 | -27.27% |
| Jun 30, 2023 | 22.25% |
| Mar 31, 2023 | -2.41% |
| Dec 31, 2022 | -18.74% |
| Sep 30, 2022 | 7.58% |
| Jun 30, 2022 | 16.44% |
| Mar 31, 2022 | 48.79% |
| Dec 31, 2021 | 55.62% |
| Sep 30, 2021 | 23.15% |
| Jun 30, 2021 | 13.47% |